Morgan Stanley has published a research report on Medtronic MDT.
In the report, Morgan Stanley wrote, "Expectations were low into the F1Q12 quarter, and given relatively in line results, achievable guidance (although less conservative than management thought), and comments from new CEO Omar Ishrak that change is needed, we expect Medtronic to stabilize above its historical trough valuation of 9x CY12 EPS."
Morgan Stanley rated Medtronic an Equal-weight with a price target of $37.00. Medtronic closed Tuesday at $33.10.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in